AR046068A1 - Anticuerpos de factor tisular y uso de los mismos - Google Patents

Anticuerpos de factor tisular y uso de los mismos

Info

Publication number
AR046068A1
AR046068A1 ARP040101371A ARP040101371A AR046068A1 AR 046068 A1 AR046068 A1 AR 046068A1 AR P040101371 A ARP040101371 A AR P040101371A AR P040101371 A ARP040101371 A AR P040101371A AR 046068 A1 AR046068 A1 AR 046068A1
Authority
AR
Argentina
Prior art keywords
antibody
antibodies
same
conjugated
methods
Prior art date
Application number
ARP040101371A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR046068A1 publication Critical patent/AR046068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos capaces de unirse al factor tisular humano, que no inhiben la coagulación sanguínea mediada por el factor tisular comparados con un plasma normal y que pueden iniciar un mecanismo mediador por FC. Asimismo se describen métodos para la preparación y métodos de uso terapéutico de los anticuerpos para el tratamiento del cancer. Polinucleótidos que codifican dichos anticuerpos así como hibridonas que los rpoducen, vector, célula huesped y kits que comprenden las composiciones farmacéuticas. Reivindicación 6:El anticuerpo de la reivindicación 1, donde dicho anticuerpo está conjugado a un agente citotóxico. Reivindicación 8:El anticuerpo de la reivindicación 1, dodne dicho anticuerpo está conjugado a un agente detectable.
ARP040101371A 2003-04-22 2004-04-22 Anticuerpos de factor tisular y uso de los mismos AR046068A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46436303P 2003-04-22 2003-04-22
US48249803P 2003-06-26 2003-06-26
US10/816,938 US7425328B2 (en) 2003-04-22 2004-04-05 Tissue factor antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AR046068A1 true AR046068A1 (es) 2005-11-23

Family

ID=33314255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101371A AR046068A1 (es) 2003-04-22 2004-04-22 Anticuerpos de factor tisular y uso de los mismos

Country Status (9)

Country Link
US (2) US7425328B2 (es)
EP (1) EP1618134A2 (es)
JP (1) JP2007525944A (es)
AR (1) AR046068A1 (es)
AU (1) AU2004233006A1 (es)
CA (1) CA2523244A1 (es)
CL (1) CL2004000859A1 (es)
NZ (1) NZ543690A (es)
WO (1) WO2004094475A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
WO2004110363A2 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
DE10338733A1 (de) * 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
WO2006088741A2 (en) * 2005-02-16 2006-08-24 The Board Of Trustees Of The University Of Illinois Procoagulants based on metal-chelating lipids
ATE505488T1 (de) 2005-03-04 2011-04-15 Univ Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP1918304A1 (en) 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008103812A1 (en) * 2007-02-21 2008-08-28 Yale University Compositions and methods for diagnosing and treating endometriosis
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
WO2009046194A2 (en) 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
PT2307051E (pt) 2008-07-08 2015-05-21 Oncomed Pharm Inc Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN102325903B (zh) 2009-02-20 2015-06-03 弗·哈夫曼-拉罗切有限公司 得到免疫球蛋白编码核酸的方法
DK2483289T3 (da) 2009-10-02 2019-06-11 Biogen Ma Inc Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
EP2308896A1 (en) * 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2319871A1 (en) * 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
BR112012007821A2 (pt) * 2009-10-09 2017-05-30 Sanofi Sa polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
AU2011205316B2 (en) * 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
KR20130079384A (ko) * 2010-05-03 2013-07-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
PT2582728T (pt) 2010-06-15 2017-11-23 Genmab As Conjugados fármaco-anticorpo humano contra fator tecidual
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
JP6236383B2 (ja) * 2011-05-13 2017-11-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． トリスルフィド結合を防止および除去する方法
RU2015131718A (ru) * 2013-03-14 2017-04-19 Онкомед Фармасьютикалс, Инк. Мет-связывающие агенты и их применения
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP6640076B2 (ja) 2013-03-15 2020-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 代謝と細胞生存を調節するミトコンドリア由来のペプチドｍｏｔｓ３
EP3103811A4 (en) * 2014-02-03 2017-11-29 National Cancer Center Anti-tissue factor monoclonal antibody
EP3274367A1 (en) * 2015-03-23 2018-01-31 Dana Genetic A/S Recombinant soluble human tissue factor, method of its production and uses thereof
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRAL NEOANTIGENIC VECTORS
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
MX2020005473A (es) * 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
AU2019205330A1 (en) * 2018-01-04 2020-08-27 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
AU2020282369A1 (en) 2019-05-30 2022-01-20 Gritstone Bio, Inc. Modified adenoviruses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
AU5093593A (en) 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
WO1996001653A1 (en) 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5932449A (en) * 1996-02-01 1999-08-03 The United States Of America As Represented By The Secretary Of The Army Detection of botulinum toxin
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
CA2325346A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
PT1198479E (pt) 1999-07-01 2008-08-12 Univ Yale Imunoconjugados direccionados para alvos neovasculares
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
JP2003527861A (ja) 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
US6703494B2 (en) * 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20030124117A1 (en) * 2000-03-16 2003-07-03 Refino Canio J. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
CN1489474A (zh) * 2001-01-26 2004-04-14 Ӣϣ��̩��˹��˾ 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
US20030143225A1 (en) 2001-03-08 2003-07-31 Genentech, Inc. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
WO2003020111A2 (en) 2001-08-30 2003-03-13 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003092602A2 (en) 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof

Also Published As

Publication number Publication date
CA2523244A1 (en) 2004-11-04
US7425328B2 (en) 2008-09-16
NZ543690A (en) 2009-04-30
WO2004094475A2 (en) 2004-11-04
WO2004094475A3 (en) 2005-03-17
EP1618134A2 (en) 2006-01-25
US20040229301A1 (en) 2004-11-18
US7993644B2 (en) 2011-08-09
CL2004000859A1 (es) 2005-03-18
US20090081200A1 (en) 2009-03-26
AU2004233006A1 (en) 2004-11-04
JP2007525944A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
AR046068A1 (es) Anticuerpos de factor tisular y uso de los mismos
CL2022003747A1 (es) Anticuerpos ccr8 para aplicaciones terapéuticas
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
AR100225A2 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
BRPI0512583A (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
AR032743A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR112014009276A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
UY29245A1 (es) Combinaciones medicas
BRPI0516661A (pt) epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal
UY28130A1 (es) Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso.
UY29244A1 (es) Combinaciones medicas
ECSP15028696A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados

Legal Events

Date Code Title Description
FB Suspension of granting procedure